Clinical Trial Update: Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of canakinumab in pediatric patients with Kawasaki disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kawasaki Disease | Phase 2 | Status: WITHDRAWN